3-[[2-(Trifluoromethyl)phenyl]methyl]azetidine | 937626-43-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-[[2-(Trifluoromethyl)phenyl]methyl]azetidine
• CAS: 937626-43-2
• 化学式: C₁₁H₁₂F₃N
• mdl: MFCD09052846
• 分子量: 215.21
• InChiKey: XSKYCFKNAZOGIJ-UHFFFAOYSA-N

物化性质

• 沸点：
  232.9±35.0 °C(Predicted)
• 密度：
  1.203±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Azetidine Derivatives as Inhibitors of Stearoyl-Coenzyme a Delta-9 Desaturase
  申请人：Isabel Elise

  公开号：US20090170828A1

  公开（公告）日：2009-07-02

  Azetidine derivatives of structural formula I are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease; atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; liver steatosis; and non-alcoholic steatohepatitis. (I)

  结构式I的氮杂环丙烷衍生物是选择性抑制硬脂酰辅酶A delta-9去饱和酶(SCD1)的化合物，相对于其他已知的硬脂酰辅酶A去饱和酶。本发明的化合物可用于预防和治疗与异常脂质合成和代谢相关的疾病，包括心血管疾病；动脉粥样硬化；肥胖症；糖尿病；神经系统疾病；代谢综合征；胰岛素抵抗；肝脂肪变性和非酒精性脂肪性肝炎。
• [EN] AZETIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE<br/>[FR] DÉRIVÉS D'AZÉTIDINE COMME INHIBITEURS DE LA STÉAROYL-COENZYME A DELTA-9 DÉSATURASE
  申请人：MERCK FROSST CANADA LTD

  公开号：WO2007143823A1

  公开（公告）日：2007-12-21

  [EN] Azetidine derivatives of structural formula I are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease; atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; liver steatosis; and non-alcoholic steatohepatitis. (I)
  [FR] L'invention concerne des dérivés d'azétidine de formule structurelle I qui sont des inhibiteurs sélectifs de la stéaroyl-coenzyme A delta-9 désaturase (SCD1) relativement à d'autres stéaroyl-coenzyme A delta-9 désaturases connues. Les composés de la présente invention sont utiles pour la prévention et le traitement d'états liés à une synthèse et à un métabolisme lipidiques anormaux, y compris les maladies cardiovasculaires, l'athérosclérose, l'obésité, le diabète, les maladies neurologiques, le syndrome métabolique, la résistance à l'insuline, la stéatose hépatique et la stéatohépatite non alcoolique. (I)